PHARMACY

Survey: Endocrinologists would prescribe Bydureon for 20% of patients

BY Alaric DeArment

BURLINGTON, Mass. — Endocrinologists would prescribe a newly approved weekly treatment for Type 2 diabetes to one-fifth of their patients, a new survey showed.

Healthcare market research firm Decision Resources announced the results of a survey of endocrinologists in the United States who said they would prescribe Bydureon (exenatide), made by Amylin Pharmaceuticals and Alkermes, to 20% of their patients. But taking into consideration the reimbursement hurdles and competition that the drug could face, the firm said Bydureon probably would earn a 2.6% share of the Type 2 diabetes market by 2020.

"However, we expect Bydureon will displace Victoza (liraglutide) and will earn our proprietary gold-standard status for Type 2 diabetes in 2015," Decision Resources analyst Christine Helliwell said, referring to a competing drug made by Novo Nordisk. "Bydureon has competitive advantages in efficacy, safety, tolerability and delivery."

The Food and Drug Administration approved Bydureon on Monday. The drug, a long-acting version of the injected drug Byetta, was developed under a partnership between Amylin and Eli Lilly & Co. that started in 2002 but that the companies dissolved in November 2011 after Lilly formed a similar diabetes drug partnership with Boehringer Ingelheim.

 


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Teva launches generic schizophrenia, bipolar disorder drug

BY Alaric DeArment

NORTH WALES, Pa. — Teva Pharmaceuticals has launched a generic version of a psychiatric drug, the company said Friday.

Teva announced the launch of olanzapine orally disintegrating tablets in the 5-mg, 10-mg, 15-mg and 20-mg strengths in blister packs of 30.

The drug is a generic version of Eli Lilly’s Zyprexa Zydis, used to treat schizophrenia and bipolar disorder.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

DannyHaszard says:
Feb-03-2012 01:50 pm

Eli Lilly did make $65 billion on Zyprexa and they still expect to capture 20% of the US market as well as a billion year on Zyprexa XR.- Association Between Zyprexa and Hyperglycemia. There is concern Zyprexa,like other atypical antipsychotic drugs, has the potential to cause metabolic disorders, particularly hyperglycemia (excess sugar) and diabetes. Atypical antipsychotics cause the body to metabolize fat instead of carbohydrates, leading to insulin resistance to the excess carbohydrates. At the same time they promote fat accumulation.I was a patient back in 1996-2000 who was a subject of Eli Lilly's Zyprexa 'viva' Zyprexa' off label sales promotion.I was given it as an ineffective costly treatment for PTSD It gave me diabetes as a side effect.--Daniel Haszard

TRENDING STORIES

PHARMACY

American Diabetes Association appoints chief scientific and medical officer

BY Allison Cerra

ALEXANDRIA, Va. — The American Diabetes Association has appointed Robert Ratner to serve as chief scientific and medical officer of the organization, effective May 7.

In his role, Ratner will serve as the primary medical and scientific representative and spokesman for the association’s scientific and medical affairs, research program and other clinical activities. Ratner also will oversee the planning, development and implementation of a wide variety of strategic scientific and medical programs to support and advance the association’s mission. He currently serves as a professor of medicine at Georgetown University Medical School and senior research scientist at the MedStar Health Research Institute.

"Bob Ratner is one of the brightest and most respected minds in diabetes," American Diabetes Association CEO Larry Hausner said. "He brings a remarkable breadth of experience to this vital role, and I am confident that his leadership and vision will be a strong guiding force in helping the Association achieve our strategic priorities and further our mission."


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES